Identification and characterization of Toxoplasma gondii aspartic protease 1 as a novel vaccine candidate against toxoplasmosis

Parasites and Vectors

Volumn 6, Issue 1, 2013, Pages

  Zhao, Guanghui ^a   Zhou, Aihua ^a   Lu, Gang ^a   Meng, Min ^a   Sun, Min ^a   Bai, Yang ^a   Han, Yali ^a   Wang, Lin ^a   Zhou, Huaiyu ^a   Cong, Hua ^a   Zhao, Qunli ^a   Zhu, Xing Quan ^b   He, Shenyi ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Aspartic protease; Bioinformatics; Toxoplasma gondii; Toxoplasmosis; Vaccine

Indexed keywords

BRINASE; DNA VACCINE; MEMBRANE PROTEIN; TOXOPLASMA GONDII VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; IMMUNE RESPONSE; MORTALITY; MOUSE; NONHUMAN; PARASITE; TOXOPLASMOSIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ASPARTIC ACID ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TH1 CELLS; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; VACCINES, DNA; VACCINES, SYNTHETIC;

ESCHERICHIA COLI; MUS; TOXOPLASMA GONDII;

EID: 84878895912     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/1756-3305-6-175     Document Type: Article

References (47)

1. Toxoplasma gondii infection in humans in China. Zhou P, Chen Z, Li HL, Zheng H, He S, Lin RQ, Zhu XQ, Parasit Vectors 2011 4 165 10.1186/1756-3305-4- 165 21864327
2. Seroprevalence of Toxoplasma gondii infection in household and stray cats in Lanzhou, northwest China. Wu SM, Zhu XQ, Zhou DH, Fu BQ, Chen J, Yang JF, Song HQ, Weng YB, Ye DH, Parasit Vectors 2011 4 214 10.1186/1756-3305-4-214 22071006
3. Seroprevalence and risk factors for Toxoplasmosis in HIV infected and non-infected individuals in Bahir Dar. Walle F, Kebede N, Tsegaye A, Kassa T, Northwest Ethiopia. Parasit Vectors 2013 6 1 15 10.1186/1756-3305-6-15
4. Congenital toxoplasmosis from a chronically infected woman with reactivation of retinochoroiditis during pregnancy. Andrade GM, Vasconcelos-Santos DV, Carellos EV, Romanelli RM, Vitor RW, Carneiro AC, Januario JN, J Pediatr (Rio J) 2010 86 1 85 88 Review 10.1590/S0021- 75572010000100015
5. Role of proteases in host cell invasion by Toxoplasma gondii and other Apicomplexa. Kim K, Acta Trop 2004 91 1 69 81 10.1016/j.actatropica.2003.11.016 15158690 (Pubitemid 38670386)
6. Targeted disruption of Toxoplasma gondii serine protease inhibitor 1 increases bradyzoite cyst formation in vitro and parasite tissue burden in mice. Pszenny V, Davis PH, Zhou XW, Hunter CA, Carruthers VB, Roos DS, Infect Immun 2012 80 3 1156 1165 10.1128/IAI.06167-11 22202120
7. How pathogen-derived cysteine proteases modulate host immune responses. Donnelly S, Dalton JP, Robinson MW, Adv Exp Med Biol 2011 712 192 207 10.1007/978-1-4419-8414-2-12 21660666
8. Toxoplasma gondii toxolysin4 is anextensively rocessed putative metalloproteinase secreted from micronemes. Laliberté J, Carruthers VB, Mol Biochem Parasitol 2011 177 1 49 56 10.1016/j.molbiopara.2011.01.009 21277910
9. Cathepsin proteases in Toxoplasma gondii. Dou Z, Carruthers VB, Adv Exp Med Biol 2011 712 49 61 10.1007/978-1-4419-8414-2-4 21660658
10. The cathepsin B of Toxoplasma gondii, toxopain-1, is critical for parasite invasion and rhoptry protein processing. Que X, Ngo H, Lawton J, Gray M, Liu Q, et al. J Biol Chem 2002 277 28 25791 25797 10.1074/jbc.M202659200 12000756 (Pubitemid 34951900)
11. Location, location, location: trafficking and function of secreted proteases of Toxoplasma and Plasmodium. Binder EM, Kim K, Traffic 2004 5 12 914 24 10.1111/j.1600-0854.2004.00244.x 15522094 (Pubitemid 39534484)
12. Suppression of dendritic cell-mediated responses by genes in calcium and cysteine protease pathways during Mycobacterium tuberculosis infection. Singhal J, Agrawal N, Vashishta M, Priya NG, Tiwari BK, Singh Y, Raman R, Natarajan K, J Biol Chem 2012 287 14 11108 11121 10.1074/jbc.M111.300319 22337888
13. Using protease inhibitors in antigen presentation assays. Basler M, Groettrup M, Methods Mol Biol 2013 960 31 39 10.1007/978-1-62703-218-6-3 23329476
14. Toxoplasma gondii aspartic protease1 is not essential in tachyzoites. Polonais V, Shea M, Soldati-Favre D, Exp Parasitol 2011 128 4 454 459 10.1016/j.exppara.2011.05.003 21616070
15. Plasmodium food vacuole plasmepsins are activated by falcipains. Drew ME, Banerjee R, Uffman EW, Gilbertson S, Rosenthal PJ, Goldberg DE, J Biol Chem 2008 283 19 12870 12876 10.1074/jbc.M708949200 18308731
16. A family of aspartic proteases and a novel, dynamic and cell-cycle-dependent protease localization in the secretory pathway of Toxoplasma gondii. Shea M, Jäkle U, Liu Q, Berry C, Joiner KA, Soldati-Favre D, Traffic 2007 8 8 1018 1034 10.1111/j.1600-0854.2007.00589.x 17547703 (Pubitemid 47074036)
17. Development of a vaccine for toxoplasmosis: current status. Bhopale GM, Microbes Infect 2003 5 5 457 462 10.1016/S1286-4579(03)00048-0 12738002 (Pubitemid 36549188)
18. DNA vaccines and recombinant antigens in prevention of Toxoplasma gondii infections-current status of the studies. Hiszczynska-Sawicka E, Holec-Gasior L, Kur J, Wiad Parazytol 2009 55 2 125 139 19670528
19. Molecular tools for genetic dissection of the protozoan parasite Toxoplasma gondii. Roos DS, Donald RG, Morrissette NS, Moulton AL, Methods Cell Biol 1994 45 27 63 7707991
20. Toxoplasma gondii immune mapped protein-1 (TgIMP1) is a novel vaccine candidate against toxoplasmosis. Cui X, Lei T, Yang D, Hao P, Li B, Liu Q, Vaccine 2012 30 13 2282 2287 10.1016/j.vaccine.2012.01.073 22310204
21. The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against Toxoplasmosis. Ismael AB, Sekkai D, Collin C, Bout D, Mévélec MN, Infect Immun 2003 71 11 6222 6228 10.1128/IAI.71.11. 6222-6228.2003 14573640 (Pubitemid 37337678)
22. Rapid invasion of host cells by Toxoplasma requires secretion of the MIC2-M2AP adhesive protein complex. Huynh MH, Rabenau KE, Harper JM, Beatty WL, Sibley LD, Carruthers VB, EMBO J 2003 22 9 2082 2090 10.1093/emboj/cdg217 12727875 (Pubitemid 36565533)
23. Molecular characterisation of a novel family of cysteine- rich proteins of Toxoplasma gondii and ultrastructuralevidence of oocyst wall localisation. Possenti A, Cherchi S, Bertuccini L, Pozio E, Dubey JP, Spano F, Int J Parasitol 2010 40 14 1639 1649 10.1016/j.ijpara.2010.06.009 20708619
24. Induction of protective immune responses by a multiantigenic DNA vaccine encoding GRA7 and ROP1 of Toxoplasma gondii. Quan JH, Chu JQ, Ismail HA, Zhou W, Jo EK, Cha GH, Lee YH, Clin Vaccine Immunol 2012 19 5 666 674 10.1128/CVI.05385-11 22419676
25. Protective effect against toxoplasmosis in mice induced by DNA immunization with gene encoding Toxoplasma gondii ROP18. Yuan ZG, Zhang XX, Lin RQ, Petersen E, He S, Yu M, He XH, Zhou DH, He Y, Li HX, Liao M, Zhu XQ, Vaccine 2011 29 38 6614 6619 10.1016/j.vaccine.2011.06.110 21762755
26. Effect of codon optimization and subcellular targeting on Toxoplasma gondii antigen SAG1 expression in tobacco leaves to use in subcutaneous and oral immunization in mice. Laguía-Becher M, Martín V, Kraemer M, Corigliano M, Yacono ML, Goldman A, Clemente M, BMC Biotechnol 2010 10 52 10.1186/1472-6750-10-52 20633272
27. Toxoplasma gondii microneme protein 6 (MIC6) is a potential vaccine candidate against toxoplasmosis in mice. Peng GH, Yuan ZG, Zhou DH, He XH, Liu MM, Yan C, Yin CC, He Y, Lin RQ, Zhu XQ, Vaccine 2009 27 47 6570 6574 10.1016/j.vaccine.2009.08.043 19720368
28. Protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing TgAMA1 as vaccines against Toxoplasma gondii infection in mice. Yu L, Yamagishi J, Zhang S, Jin C, Aboge GO, Zhang H, Zhang G, Tanaka T, Fujisaki K, Nishikawa Y, Xuan X, Parasitol Int 2012 61 3 481 486 10.1016/j.parint.2012.04.001 22537971
29. Humane and practical implications of using carbon dioxide mixed with oxygen for anesthesia or euthanasia of rats. Danneman PJ, Stein S, Walshaw SO, Lab Anim Sci 1997 47 4 376 385 9306311
30. Tools and collaborative environments for bioinformatics research. Romano P, Giugno R, Pulvirenti A, Brief Bioinform 2011 12 6 549 561 10.1093/bib/bbr055 21984743
31. GOtcha: a new method for prediction of protein function assessed by the annotation of seven genomes. Martin DM, Berriman M, Barton GJ, BMC Bioinfo rmatics 2004 5 178 10.1186/1471-2105-5-178 (Pubitemid 40195331)
32. Toxoplasma gondii: bioinformatics analysis, cloning and expression of a novel protein TgIMP1. Bai Y, He S, Zhao G, Chen L, Shi N, Zhou H, Cong H, Zhao Q, Zhu XQ, Exp Parasitol 2012 132 4 458 64 10.1016/j.exppara.2012.09.015 23026454
33. Optimized signal peptides for the development of high expressing CHO cell lines. Kober L, Zehe C, Bode J, Biotechnol Bioeng 2012 110 4 1164 1173
34. Mesenchymal stem cell effects on T-cell effector pathways. Duffy MM, Ritter T, Ceredig R, Griffin MD, Stem Cell Res Ther 2011 2 4 34 10.1186/scrt75 21861858
35. Coffman RL: TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Mosmann TR, Annu Rev Immunol 1987 7 145 73 (Pubitemid 19138011)
36. Lymphocyte responses and cytokines. Paul WE, Seder RA, Cell 1994 76 2 241 251 10.1016/0092-8674(94)90332-8 7904900
37. Laurie H Glimcher: transcription: tantalizing times for T cells. Ho I-C, Cell 2002 109 2 109 120 10.1016/S0092-8674(02)00705-5 (Pubitemid 34457856)
38. DNA vaccination with the immunodominant tachyzoite surface antigen (SAG-1) protects against adult acquired Toxoplasma gondii infection but does not prevent maternofoetal transmission. Couper KN, Nielsen HV, Petersen E, Roberts F, Roberts CW, Alexander J, Vaccine 2003 21 21-22 2813 2820 12798622 (Pubitemid 36703192)
39. Evaluation of immune responses in sheep induced by DNA immunization with genes encoding GRA1, GRA4, GRA6 and GRA7 antigens of Toxoplasma gondii. Hiszczyńska-Sawicka E, Olȩdzka G, Holec-Ga̧sior L, Li H, Xu JB, Sedcole R, Kur J, Bickerstaffe R, Stankiewicz M, Vet Parasitol 2011 177 3-4 281 289 21251760
40. Toxoplasma gondii: humoral and cellular immune response of BALB/c mice immunized via intranasal route with rTgROP2. Igarashi M, Zulpo DL, Cunha IA, Barros LD, Pereira VF, Taroda A, Navarro IT, Vidotto O, Vidotto MC, Jenkins MC, Garcia JL, Rev Bras Parasitol Vet 2010 19 4 210 216 10.1590/S1984- 29612010000400004 21184696
41. Immunization with MIC1 and MIC4 induces protective immunity against Toxoplasma gondii. Barreira MC, Microbes Infect 2006 8 5 1244 1251 10.1016/j.micinf.2005.11.013 16616574 (Pubitemid 43831688)
42. Genetic mapping identifies novel highly protective antigens for an apicomplexan parasite. Blake DP, Billington KJ, Copestake SL, Oakes RD, Quail MA, Wan KL, Shirley MW, Smith AL, PLoS Pathog 2011 7 2 1001279 10.1371/journal.ppat.1001279 21347348
43. MVA ROP2 vaccinia virus recombinant as a vaccine candidate for toxoplasmosis. Roque-Reséndiz JL, Rosales R, Herion P, Parasitology 2004 128 Pt 4 397 405 15151145 (Pubitemid 38621699)
44. Immunogenicity of recombinant BCG producing the GRA1 antigen from Toxoplasma gondii. Supply P, Sutton P, Coughlan SN, Bilo K, Saman E, Trees AJ, Cesbron Delauw MF, Locht C, Vaccine 1999 17 7-8 705 714 10067676 (Pubitemid 29074724)
45. Comparison of cholera toxin A2/B and murine interleukin-12 as adjuvants of Toxoplasma multi-antigenic SAG1-ROP2 DNA vaccine. Xue M, He S, Zhang J, Cui Y, Yao Y, Wang H, Exp Parasitol 2008 119 3 352 357 10.1016/j.exppara.2008.03.005 18442818
46. Effect of various digestive enzymes on the interaction of Toxoplasma gondii with macrophages. de Carvalho L, Yan CY, de Souza W, Parasitol Res 1993 79 2 114 118 10.1007/BF00932256 8475028 (Pubitemid 23072160)
47. Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection. Sánchez VR, Pitkowski MN, Fernández Cuppari AV, Rodríguez FM, Fenoy IM, Frank FM, Goldman A, Corral RS, Martin V, Exp Parasitol 2011 128 4 448 453 10.1016/j.exppara.2011.04.004 21554876